Aim: The present study aims to reveal direct cost analysis of patients with severe allergic asthma receiving omalizumab treatment.
 Material and Methods: Twenty-two adults who were treated routinely checked on the 16th week, 1st year, 3rd year treatment included in study. Clinical demographic features subjects retrospectively documented before after as well pharmaceutical, emergency hospit...